Close Menu

NEW YORK (Precision Oncology News) – The UK's National Institute for Health and Care Excellence (NICE) has issued a final draft guidance recommending blinatumomab (Amgen's Blincyto) for treating acute lymphoblastic leukemia in patients experiencing a first complete remission with minimal residual disease (MRD) activity of at least 0.1 percent.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.